StockData
GENELUX Corp logo

GENELUX Corp (GNLX) stock

GNLXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 5/30
$1.92+0.05 (+2.95%)

Close on Nov 16, 2026Market cap $86.87MP/E –Yield –

Genelux EPS

Diluted earnings per share is net income divided by the share count including options and convertible securities.

Genelux's EPS for the twelve months ending Jun 30, 2026 was -$0.86. For fiscal 2025 it was -$0.86.

Annual eps

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$0.86–
FY2024Dec 31, 2024-$0.95–
FY2023Dec 31, 2023-$1.16–
FY2022Dec 31, 2022-$0.57–

Quarterly eps

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$0.21–
Q1 FY2026Mar 31, 2026-$0.20–
Q4 FY2025Dec 31, 2025-$0.24–
Q3 FY2025Sep 30, 2025-$0.21–
Q2 FY2025Jun 30, 2025-$0.20–
Q1 FY2025Mar 31, 2025-$0.21–
Q4 FY2024Dec 31, 2024-$0.26–
Q3 FY2024Sep 30, 2024-$0.19–
Q2 FY2024Jun 30, 2024-$0.22–
Q1 FY2024Mar 31, 2024-$0.29–
Q4 FY2023Dec 31, 2023-$0.25-151.0%
Q3 FY2023Sep 30, 2023-$0.20-164.5%
Q2 FY2023Jun 30, 2023-$0.23–
Q1 FY2023Mar 31, 2023-$0.53–
Q3 FY2022Sep 30, 2022$0.49–
Q2 FY2022Jun 30, 2022$0.31–

More Genelux figures

See a number that looks wrong?